Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Palisade Bio Inc

PALI ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$2.14

▼ -0.47%

Market Cap $372.94M · Vol 375.01K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$372.94M

Small Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+27.41%

YoY

RSI (14)

56.55

Momentum

Beta

1.58

vs Market

52W High

$2.85

24.91% below

52W Low

$0.53

303.77% above

Volume

375.01K

Avg 512.10K

P/B

2.90

Price-to-book

ROE

N/A

Return on equity

Free Float

91.69%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Palisade Bio Inc (PALI) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PALI pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.42%

+10.88%

+18.23%

+23.70%

YTD

-8.94%

+162.58%

-77.48%

-99.89%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-16,781,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-23.11% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.90
P/FCF	N/A
EPS Growth	+27.41%
Outstanding Shares	174.27M

Technical Indicators

50-Day SMA	$1.95
200-Day SMA	$1.93
RSI (14)	56.55
Beta	1.58
52-Week High	$2.85
52-Week Low	$0.53

Volume Today	375.01K
Avg Daily Volume (30D)	512.10K
Relative Volume	0.73x
Volatility (10D)	72.15
Volatility (30D)	62.08
Free Float	91.69%

Analyst Consensus

BUY

Current Price $2.14

Mean Target $10.40

52W Low$0.53 52W High$2.85

Current

Target

$0.53 $2.85

Current Analyst target

+385.98% upside potential · 9 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SS4KZ8

ISINUS6963894026

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.